Catalent Pharma Solutions and NewMarket Pharmaceuticals have entered into an agreement to jointly formulate and develop a portfolio of products for treating production and companion animals using Catalent’s Zydis fast-dissolve technology and NewMarket’s DSI platform (Direct Systemic Introduction, patent pending). NewMarket is currently developing five drugs that will combine Catalent’s Zydis fast-dissolve and its DSI technologies, initially including NSAIDs, beta agonists, proton pump inhibitor...